학술논문

Combining the androgen receptor inhibitor darolutamide with PI3K/AKT/mTOR pathway inhibitors has superior efficacy in preclinical models of prostate cancer
Document Type
Journal
Source
CANCER RESEARCH; JUN 1 2023, 83 11, 3p. Supplement: S
Subject
Language
English
ISSN
15387445